The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Chan CheahDuring the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked for an update on novel therapies in chronic lymphocytic leukemia (CLL).
Novel therapies in chronic lymphocytic leukemia: An update
Cheah reviews the abstracts that were presented at ASH on novel BTK inhibitors and Bcl-2 inhibitors for relapsed/refractory CLL. This includes an analysis of the potency, toxicity, and MRD response rates of the Bcl-2 inhibitor, BGB-11417, as well as the results of the phase I/II BRUIN study of the non-covalent BTK inhibitor, pirtobrutinib, in heavily pretreated patients with CLL and patients with Richter’s transformation.